Remove Cardiology Remove Dermatology Remove Regulation
article thumbnail

Pfizer buys immuno-inflammatory firm Arena Pharmaceuticals for $6.7b

Outsourcing Pharma

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog

These have included clinical trials for rare diseases across metabolic (n=5), oncology (n=5), cardiology (n=3), dermatology (n=3), pulmonary (n=3), hematology (n=2), hepatology (n=2), ocular (n=2), transplant (n=1), gastrointestinal (n=1), immunology (n=1), infectious (n=1), neurology (n=1), orthopedic (n=1), and toxicology (n=1) indications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nine for 2021: The COVID-19 legacy

pharmaphorum

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.

Sales 105
article thumbnail

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis

The Pharma Data

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. Adakveo sales reached USD 37 million. The safety profile of Entresto was confirmed.

Sales 40
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. The TPO receptor agonist regulates blood platelet production by binding to and activating TPO receptors on megakaryocyte cells and inducing signalling cascades that increase platelet production.

Sales 98
article thumbnail

Audience Engagement Strategies for Pharma Marketing: Boost HCP and Patient Interaction

Pharma Marketing Network

Introduction In the highly regulated pharmaceutical industry, audience engagement is more than just a marketing goalit is a necessity for building trust with healthcare professionals (HCPs) and patients. But how can pharma brands create meaningful connections in a digital landscape crowded with content?